Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a switch to guselkumab clear stubborn psoriasis?

NCT ID NCT07746583

Disease control Sponsor: Janssen-Cilag Kft. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 28, 2026 · Updated 2 times

Summary

This study looks at how well guselkumab works for people with moderate to severe psoriasis who switch from ustekinumab (or its biosimilar) in a real-world setting. Researchers will track skin clearance using the PASI score at various time points over a year. The goal is to see if the switch helps reduce psoriasis severity and is safe in routine clinical care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Guselkumab (a biologic drug) given after switching from ustekinumab
What this could lead to
If successful, this could help doctors understand whether switching to guselkumab is a safe and effective option for people with moderate to severe psoriasis in everyday practice.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may be influenced by patient differences, and the study is relatively small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with moderate-to-severe psoriasis who are candidates for systemic treatment (according to the Guselkumab label) and who are medically indicated to switch from Ustekinumab or its biosimilar to Guselkumab can be included in this study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Must have a confirmed diagnosis of moderate-to-severe plaque psoriasis requiring systemic treatment * Participants who are currently being treated with Ustekinumab (either the originator or its biosimilar) and who are medically indicated to switch to Guselkumab, or for whom this switch is medically indicated, based on the current and valid national psoriasis (PsO) therapeutic protocol * Participants who, based on the Investigator's decision, should initiate treatment with Guselkumab * Participants must sign an informed consent form (ICF) allowing for data collection and source data verification in accordance with local requirements Exclusion criteria: * Contraindication or hypersensitivity to Guselkumab or any other ingredient in the injection solution * Pregnancy or breastfeeding * Currently enrolled in an interventional study * Currently enrolled in an observational study sponsored or managed by a Janssen company * Previous use of guselkumab in any indication in participant history

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Semmelweis University

    RECRUITING

    Budapest, 1088, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.